4/A: Sanitam Partners Acquires Preferred Stock and Warrants in Matinas BioPharma Holdings
SEC Form 4/A Filing
Sanitam Partners LLC reports acquisition of Series C Convertible Preferred Stock and warrants in Matinas BioPharma Holdings, Inc., impacting beneficial ownership.
Summary
- Sanitam Partners LLC filed a Form 4/A with the SEC on April 9, 2025, reporting changes in beneficial ownership of Matinas BioPharma Holdings, Inc. securities.
- The filing indicates that Sanitam Partners purchased 1,406 shares of Series C Convertible Preferred Stock and 4,798,636 warrants for gross proceeds of $1,406,000 on April 8, 2025.
- The preferred stock has a stated value of $1,000 per share and a conversion price of $0.6393 per share, granting Sanitam voting power of up to 30.2% of the outstanding common stock.
- Sanitam's beneficial ownership is subject to a 9.99% limit on common stock issuable upon conversion of the preferred stock and a 4.99% limit on common stock issuable upon exercise of the warrants.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The document simply reports a transaction. The investment by Sanitam Partners could be viewed as a positive, but the filing itself is a standard regulatory requirement.
Positives
- Sanitam Partners' investment of $1,406,000 into Matinas BioPharma Holdings could be seen as a positive signal.
Risks
- The 9.99% and 4.99% limits on common stock issuable upon conversion and exercise, respectively, could restrict Sanitam's potential gains.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders and significant shareholders. This filing indicates a notable investment by Sanitam Partners in Matinas BioPharma.
Stakeholder Impact
- Shareholders may react to the news of Sanitam Partners' investment.
- The investment could potentially impact the company's financial stability and future prospects.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Date of the Securities Purchase Agreement between Sanitam and Matinas BioPharma. |
| 02/28/2025 | Date of Original Filed (Month/Day/Year) |
| 04/04/2025 | Date of Transaction |
| 04/08/2025 | Date of Earliest Transaction and purchase of preferred stock and warrants. |
| 04/08/2030 | Expiration date of the warrants. |
| 04/09/2025 | Date of filing the SEC Form 4/A. |
Keywords
Sanitam Partners, Matinas BioPharma, Series C Convertible Preferred Stock, Warrants, Beneficial Ownership, SEC Form 4, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.